Blueprint Medicines Corp. Forecast, price target & analysts
Blueprint Medicines Corp. Target price 2025 - Analyst rating & recommendation
Blueprint Medicines Corp. Classifications & Recommendation:
Blueprint Medicines Corp. Price Target
| Target Price | $126.19 |
| Price | $80.84 |
| Potential |
56.10%
register free of charge
|
| Number of Estimates | 21 |
|
21 Analysts have issued a price target Blueprint Medicines Corp. 2026 .
The average Blueprint Medicines Corp. target price is $126.19.
This is
56.10%
register free of charge
$169.00
109.05%
register free of charge
$83.00
2.67%
register free of charge
|
|
| A rating was issued by 23 analysts: 17 Analysts recommend Blueprint Medicines Corp. to buy, 5 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Blueprint Medicines Corp. stock has an average upside potential 2026 of
56.10%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 508.82 | 728.22 |
| 104.03% | 43.12% | |
| EBITDA Margin | -38.47% | -4.46% |
| 79.79% | 88.41% | |
| Net Margin | -13.40% | -9.94% |
| 93.73% | 25.81% |
21 Analysts have issued a sales forecast Blueprint Medicines Corp. 2025 . The average Blueprint Medicines Corp. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Blueprint Medicines Corp. EBITDA forecast 2025. The average Blueprint Medicines Corp. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
21 Blueprint Medicines Corp. Analysts have issued a net profit forecast 2025. The average Blueprint Medicines Corp. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.07 | -1.14 |
| 87.22% | 6.54% | |
| P/E | negative | |
| EV/Sales | 7.24 |
21 Analysts have issued a Blueprint Medicines Corp. forecast for earnings per share. The average Blueprint Medicines Corp. EPS is
This results in the following potential growth metrics and future valuations:
Blueprint Medicines Corp....
Current Blueprint Medicines Corp. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham |
Locked
➜
Locked
|
Locked | Apr 08 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Mar 17 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| Citizens Capital Markets |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Feb 14 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 14 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Feb 14 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham:
Locked
➜
Locked
|
Apr 08 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Mar 17 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
Citizens Capital Markets:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Feb 14 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 14 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Feb 14 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
